Followers | 134 |
Posts | 7040 |
Boards Moderated | 0 |
Alias Born | 02/09/2012 |
![](https://investorshub.advfn.com/uicon/323933.png?cb=1618788139)
Wednesday, February 17, 2021 9:33:55 AM
Does seem strange why Russia is involved unless a partner is lined up? There are major hurdles between the US/Russia when it comes to the FDA and of course many areas....
Fact states otherwise:
https://www.linkedin.com/pulse/myths-misconceptions-clinical-trials-russia-julia-sardaryan/
Clinical Trials in Russia in Comparative Perspective
It is hardly surprising, but clinical trials in Russia are no different from the European or American ones. The Russian national standard of clinical trials is a direct translation of ICH GCP and differs only in the spheres where the international standards intersect with particular regional regulations. Russia has been one of the most popular destinations for clinical trials outsourcing in the last couple of years. Russia attracted not only hundreds of western trials, but also many FDA inspections.
This chart is composed on the basis of the results of 113 FDA inspections in Russia, 138 FDA inspections in Germany, 110 FDA inspections in France, and 129 FDA inspections in Great Britain. This data is all that is available in the FDA databases. We excluded inspection parameters that didn’t find any issues in the countries from the chart. Unfortunately, it is complicated to make a comparison with the United States because FDA conducted thousands of inspections in its homeland and a fair comparison will demand a separate methodology.
As one can observe, the FDA inspections of Russian research sites demonstrate better results than those of the leading European countries. Russia has the highest number of sites with no deficiencies. Russian research sites demonstrate high adherence to the ethical standards, providing adequate ICFs and appropriate payments to volunteers. Clinical research in Russian sites also demonstrates high accuracy of records and strict adherence to investigational plans. Why? The answer is plainly simple: Russia is still considered a newbie in the clinical trials market, so the only way to obtain success is to try to be the best. Smooth Drug Development is also a part of this and that is why we are so concerned with ISO certifications of all major activities, constant training of our staff, development of e-solutions (e-PRO, CTMS, etc), and the advancement of clinical trials in Russia to the highest international standards.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM